"十五五"规划开局之年，上海站在建设具有全球影响力的科技创新中心和健康城市建设的新起点。在此 背景下，2月2日，中国人民政治协商会议上海市第十四届委员会第四次会议在上海开幕。 面对国家层面多层次医疗保障体系的顶层设计出台、生物医学新技术监管新政实施，以及"新质老龄 化"带来的结构性挑战，此次会议，上海市政协常委、复星国际联席CEO陈启宇以医疗、医保、医药"三 医协同"的系统思维递交多份提案，为上海在大健康产业领域构筑全球竞争优势建言献策。 陈启宇指出，当前上海生物医药产业发展正处于从"跟跑"向"并跑""领跑"跨越的关键阶段，但创新链与 产业链脱节、支付端与供给端错配、老龄化需求与服务供给失衡等仍待进一步破题。特别是在国务院 《生物医学新技术临床研究和临床转化应用管理条例》即将实施、国家医保局发布首版《商业健康保险 创新药品目录》的政策背景下，上海要充分发挥改革开放排头兵作用。 此次陈启宇提出的系列提案立足于上海作为生物医药产业高地、医疗保障改革先行区、深度老龄化超大 城市的三重定位，从临床转化体系、多层次支付保障、科学智能基础设施、产业创新生态等维度提出具 体建议。 打通生物医药前沿技术转化通道 当前，新一轮 ...

Core Insights - Shenzhen has established itself as a leading area for the biopharmaceutical industry, particularly in cell and gene therapy (CGT), supported by the introduction of the first national legislation for the sector, the "Shenzhen Special Economic Zone Cell and Gene Industry Promotion Regulations" [1] - The CGT industry in Shenzhen is projected to generate over 8.5 billion yuan in total revenue by 2024, with nearly 200 companies in the industry chain and 17 CGT products currently in clinical trials [1] - The integration of national platforms and local funding has created a robust ecosystem that accelerates the clinical transformation of CGT products [3] Group 1 - Shenzhen's policy framework includes a comprehensive support system from basic research to industrial transformation, reinforced by the "20+8" industrial cluster policy [1] - The establishment of the cell and gene industry fund at the municipal level has contributed to a synergistic ecosystem characterized by "policy guidance + platform support + capital empowerment" [3] - The "818 Order" from the State Council provides a clear compliance pathway for clinical research and application, enhancing the stability of policy expectations for technological innovation and industrial transformation [3] Group 2 - The director of the National Engineering Research Center for Key Common Technologies in the Cell Industry suggests leveraging stem cell therapies as clinical engines while developing digitalized production lines and integrated quality monitoring platforms [5] - This proposed model aims to create a closed-loop industrial ecosystem that can be replicated in other biomedical technology fields, attracting more companies to the industry chain [5] - The complete cycle of "clinical transformation (technology) → standardized production (intelligent manufacturing) → compliance regulation (quality inspection) → data feedback optimizing technology/manufacturing" is emphasized as a pathway to build a vibrant biomedical technology industry cluster [5]